Newsletter

**The Bull Report**

The Bull Report

My long term pick: VGLS

My long term pick VG Life Sciences (VGLS) is currently trading at .o6 and could be ready to explode.

 I'm looking to see if we can get a 20 to 50% gain out of VGLS this week.

Keep your eye on VGLS as great things are happening.

I will be covering VGLS over the next year.

VG Life Science is doing great things and you have a front row seat.

Take a good hard look at VGLS, before Wall Street catches wind of this incredible company.

VG Life Sciences Inc. (VGLS), discovers and develops drug therapies from two exclusively licensed platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). 

A physician-initiated Phase I clinical trial of an MDT compound in combination with Nexavar™ on Stage III and IV ovarian cancer patients is ongoing at the Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio. 

A majority-owned subsidiary, VG Energy (http://www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. Founded in 1994, the biotech company is researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS. 

Learn more http://www.vglifesciences.com

Regards,
The Bull Report

Text: PENNYS to 69302 to get my alert before the bell!

This report is for information purposes only, and is neither a solicitation or recommendation to b_u_y nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no li_ability for any losses arising from an investor's reliance on the use of this material. The Bull Report has been previously compensated fifteen thousand dollars from a third pa_rty for coverage of VGLS. The Bull Report and its affiliates or officers currently hold no shares of VGLS. The Bull Report and its affiliates or officers will pur_chase and sell shares of common stock of VGLS, in the open market at any time without notice. The Bull Report will not update its purchases and sales of VGLS in any future postings on The Bull Report's websites. Certain information included herein is forward-looking within the context of the Pri_vate Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.

Stocks covered:	Compensation:	Avg $ Volume for Period:
VGLS	Unknown compensation	UNKNOWN
Max Profit: 8.82 %	Gain at close: 0.00 %
*We think that this promoter is a part of a group of promoters.

Newsletter

VGLS - VG Life Sciences, Inc currently at.06 Apr 05, 2015 17:05